Aytu BioScience Announces Appointment of David Green as Chief Financial Officer
December 18, 2017 at 08:05 am EST
Share
Aytu BioScience, Inc. announced the appointment of David A. Green as Chief Financial Officer. Mr. Green joins Aytu BioScience to oversee the company's finance and accounting functions, and will report directly to the Chief Executive Officer. Prior to joining Aytu BioScience, Mr. Green served as Chief Accounting Officer at Intarcia Therapeutics. Prior to that, he was Chief Financial Officer of Catheter Connections, Mr. Green was CFO at Specialized Health Products International. Prior to his time serving in senior financial leadership roles at commercial stage specialty life sciences companies, Mr. Green was a Managing Director at Duff & Phelps. Mr. Green was also a founding member of Ernst & Young's Palo Alto Center for Strategic Transactions, where he advised the firm's clients on using strategic transactions to accelerate growth.
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Companyâs Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Companyâs prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.